X0202 SCHEDULE 13G/A 0001193125-24-244251 0001875620 XXXXXXXX LIVE 3 Common Stock, $0.001 par value per share 06/30/2026 0001750149 Inhibikase Therapeutics, Inc. 45719W205 1000 N. WEST STREET, SUITE 1200 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 Rule 13d-1(c) Sands Capital Life Sciences Pulse Fund II, L.P. b E9 0.00 13018965.00 0.00 13018965.00 13018965.00 9.3 PN The percentages reported in this Schedule 13G are based upon 139,535,900 Shares outstanding as of August 4, 2026 (according to the Issuer's most recent 10-Q as filed with the Securities and Exchange Commission on August 11, 2026). Sands Capital Alternatives, LLC b DE 0.00 13018965.00 0.00 13018965.00 13018965.00 9.3 OO The percentages reported in this Schedule 13G are based upon 139,535,900 Shares outstanding as of August 4, 2026 (according to the Issuer's most recent 10-Q as filed with the Securities and Exchange Commission on August 11, 2026). SANDS FRANK M. b X1 0.00 13018965.00 0.00 13018965.00 13018965.00 9.3 IN HC The percentages reported in this Schedule 13G are based upon 139,535,900 Shares outstanding as of August 4, 2026 (according to the Issuer's most recent 10-Q as filed with the Securities and Exchange Commission on August 11, 2026). Inhibikase Therapeutics, Inc. 1000 N. WEST STREET, SUITE 1200, 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DELAWARE, 19801. This Schedule 13G is being filed jointly by: (i) Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), with respect to the shares of Common Stock held by it; (ii) Sands Capital Alternatives, LLC ("Sands Capital Alternatives"), the investment manager of Sands Pulse Fund II, with respect to the shares of Common Stock held by Sands Pulse Fund II; and (iii) Frank M. Sands ("Sands"), with respect to the shares of Common Stock held by Sands Pulse Fund II. Sands Pulse Fund II, Sands Capital Alternatives and Sands are together referred to herein as the "Reporting Persons". Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP LP") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund-GP, LLC ("Sands Pulse GP LLC" and, together with Sands Pulse GP LP, the "Sands General Partners") is the general partner of Sands Pulse GP LP. Sands Capital Alternatives is the investment manager of Sands Pulse Fund II and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II. Sands holds ultimate voting and investment power over securities held by Sands Pulse Fund II, and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II. Each Reporting Person and the Sands General Partners disclaim beneficial ownership of any securities beyond its pecuniary interest therein. The principal business address of each of the Reporting Persons and the Sands General Partners is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209. Sands Pulse Fund II and Sands Pulse GP LP are organized under the laws of the Cayman Islands. Sands Capital Alternatives and Sands Pulse GP LLC are organized under the laws of Delaware. Sands is a citizen of the United States. Y See rows 5 through 11 of the cover pages. The ownership disclosed in rows 5 through 11 of the cover pages does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the "Series A-1 Warrant") or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the "Series B-1 Warrant"), in each case held by Sands Pulse Fund II, each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the "Purchase Agreement"). The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the "Warrant Initial Registration Statement") if the Securities and Exchange Commission ("SEC") notifies the Issuer that it will "review" the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be "reviewed" or (even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the "Initial Exercise Date"). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable, the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1 Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time. See rows 5 through 11 of the cover pages. See rows 5 through 11 of the cover pages. See rows 5 through 11 of the cover pages. See rows 5 through 11 of the cover pages. See rows 5 through 11 of the cover pages. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Sands Capital Life Sciences Pulse Fund II, L.P. /s/ Jonathan Goodman 08/13/2026 Sands Capital Alternatives, LLC /s/ Jonathan Goodman 08/13/2026 SANDS FRANK M. /s/ Frank M. Sands 08/13/2026 Sands Capital Life Sciences Pulse Fund II, L.P. signed by Sands Capital Life Sciences Pulse Fund II-GP, L.P., its general partner, by Sands Capital Life Sciences Pulse Fund II-GP, LLC, its general partner, by Jonathan Goodman, General Counsel.